PRESS RELEASE
Paris, February 10, 2026
GENEO Capital Entrepreneur: a successful 2025, marked by two exits and the completion of its Europeanization.
In a challenging private equity market, GENEO Capital Entrepreneur had a solid year in 2025, combining value creation, liquidity, and operational support. GENEO Capital exceeded €550 million in net asset value and confirmed, through its exits, the model's ability to deliver performance. The year also marks the first concrete steps in GENEO's European expansion, with a partnership in Italy and an initial investment in Belgium.
GENEO Capital: performance, investment, and liquidity
As of December 31, 2025, GENEO Capital reached €553 million in net asset value (NAV).
In 2025, GENEO achieved:
- 3 investments and 4 reinvestments for more than €50 million
- 12 external growth transactions carried out by portfolio companies, including 5 internationally,
- 92 acquisitions made by subsidiaries since inception, including 42 internationally,
- A portfolio of 24 companies operating in more than 50 countries and 120 sites abroad,
- 470 new support initiatives (strategy, governance, external growth, positive impact, digital & innovation) via our Growth Notebook
GENEO also paid its first dividend in 2025, 42% of which was reinvested in the fund. This dynamic is part of an evergreen strongly supported by the GENEO community: nearly 70% of investors have already reinvested at least once.
Two total exits in 2025
In 2025, GENEO Capital Entrepreneur announced two complete divestitures, a significant milestone in a market where exits remain difficult:
- Human & Work, sold to Telus Health,
- ConvictionsHR, sold to Mercer France
GENEO Mezzanine: strong growth in 2025
In 2025, GENEO Mezzanine:
- made four investments and one reinvestment totaling more than €55 million
- accompanies 6 companies in total,
In a context of tighter financing, mezzanine financing emerged in 2025 as a particularly sought-after solution for executives seeking to support their growth and transformation projects. This trend is expected to continue in 2026, driven by structural needs for long-term, flexible, and non-dilutive financing.
Europeanization: first followers of the GENEO model in Italy and Belgium
GENEO is gradually rolling out its model in Europe, structuring an ecosystem based on a local community and targeted partnerships:
- In Italy: GENEO enters into partnership with Riello Investimenti (Milan), a recognized player in Italian private equity, to identify co-investment opportunities co-investment in iconic "Made in Italy" companies.
- In Belgium: first European investment with DAP (Leuze), a family-owned brokerage firm, supported in structuring, digitization, and impact projects to sustain its growth trajectory.
Opening up private equity to new audiences: SLPs and shared stock options
GENEO continues to expand access to Entrepreneurial Capital with new initiatives:
- SLP GENEO Executives and Entrepreneurs, invested in GENEO Capital,
- Sharing Shares, allowing 30% of dividends to be allocated to a partner association (if results allow).
Positive finance: redistribution and impact
In 2025, GENEO continued its positive finance approach by contributing €1,100,000 to the fight against climate change. €1,100,000 to the Community's endowment fund (+57% year-on-year) to the Community Endowment Fund to support associations and initiatives with an educational and social impact in the regions. This redistribution is in line with GENEO's evergreen model, which aims to reconcile sustainable financial performance, value sharing, and a positive impact on the regions.
" 2025 confirmed the strength of our model: the first two total exits of our evergreen investment company in a market where liquidity is becoming scarce, the expansion of access to entrepreneurial capital via SLP GENEO and share actions, the rise of GENEO Mezzanine, and the first concrete steps towards our Europeanization, with DAP in Belgium and our partnership with Riello Investimenti in Italy.
In 2026, we will continue this momentum with the same high standards: supporting the growth of our investments, accelerating our development in Europe, and further expanding access to Entrepreneurial Capital. "
Fanny Letier and François Rivolier, co-founders of GENEO Capital Entrepreneur
About GENEO Capital Entrepreneur
GENEO Capital Entrepreneur's raison d'être is to provide the real economy with positive finance that reconciles performance and meaning.
Designed to unlock the potential of SMEs and mid-cap companies to create value, jobs, and impact, GENEO Capital Entrepreneur has nearly €750 million under management. In particular, it manages the evergreen investment company GENEO Capital, whose capital is majority-owned by families and entrepreneurs. GENEO thus provides agile capital that adapts to the pace of each company and offers responsiveness and flexibility.
As a business partner and mission-driven company, GENEO is committed to supporting the implementation of structuring, growth, and transformation projects through a customized "Growth Plan" for each company. It draws on its teams, including its specialized business partners (external growth, liability structuring, operational and financial performance, positive impact, digital and innovation) and also has a platform of more than 70 independent experts. Its community of more than 260 families and entrepreneurs also offers a unique opportunity to share experiences and a business network that is unparalleled in France.
Passionate about those who make, create and want to move the lines, the only ambition of the GENEO team is to bring the ambition of each entrepreneur to the top.
Find out more at www.geneocapitalentrepreneur.com, LinkedIn, YouTube
Press contact
For GENEO Capital Entrepreneur: Hugues de Tournemire - 06 67 07 22 33 - h.detournemire@bcadvisory.fr
